消息面上，石四药集团此前发布公告，预计2025年度溢利将较上年度的10.61亿港元下降45%-60%。主 要由于2024年一季度国内流感爆发以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止 的整个年度因国内没有大规模流行病发生叠加医保控费导致药品终端销量下降；各种形式的带量采购范 围扩大以及国内外行业竞争加剧带来持续的价格压力；及盐酸溴己新安瓿注射液因不再通过国家药品集 采销售而营业额有所减少。 智通财经APP获悉，石四药集团(02005)午后跌超5%，截至发稿，跌5.34%，报2.66港元，成交额5290.44 万港元。 ...

Group 1: Market Overview - The Hang Seng Index fell by 0.61%, down 161 points, closing at 26,544 points, while the Hang Seng Tech Index dropped by 2.28% [1] - The Hong Kong stock market saw a morning trading volume of HKD 91.7 billion [1] Group 2: Robotics Sector - The robotics sector performed well, with First Journey Holdings (00697) rising over 11% as three invested robotics companies were featured in the 2026 Spring Festival Gala [1] - SUTENG (02498) saw a morning increase of over 9%, achieving its first quarterly profit in Q4 due to strong growth in its robotics business [1] - Hesai Technology (02525) rose by 6.7%, with two humanoid robots featured in the Spring Festival Gala equipped with Hesai's JT128 lidar [1] - Yuejiang (02432) surged by 19%, and UBTECH (09880) increased by 6.9% [1] Group 3: Oil Sector - Oil stocks were among the top gainers, driven by concerns over the Middle East situation potentially disrupting shipping in the Strait of Hormuz, with international oil prices reaching a six-month high [1] - PetroChina (00857) rose by 4.58%, CNOOC (00883) increased by 3.34%, and CNOOC Services (02883) gained 3.92% [1][2] Group 4: Semiconductor Sector - The semiconductor sector faced declines, with Hua Hong Semiconductor (01347) falling by 3.8% and SMIC dropping over 1.65% [7] Group 5: AI and Technology Sector - Zhiyuan (02513) surged by 19% after SothisAI, a subsidiary of Zhongke Shuguang, integrated with Zhiyuan's GLM-5 [3] - Aixin Yuanzhi (00600) rose over 19%, being the world's largest provider of high-end visual edge AI inference chips [4] - MiniMax (00100) increased by over 10% [3] - Extreme Intelligence (02590) saw a reverse market trend, rising over 3% after Zhao Hao, one of Tsinghua's "Five Outstanding Figures," was appointed as Chief Scientist [5] Group 6: Other Notable Movements - Stone Pharmaceutical Group (02005) fell by 5.96%, with an expected profit decline of approximately 45% to 60% year-on-year for the fiscal year 2025 [6]

智通财经APP获悉，石四药集团(02005)跌超7%，截至发稿，跌7.28%，报2.8港元，成交额257.58万港 元。 消息面上，石四药集团发布公告，预计2025年度溢利将较上年度的10.61亿港元下降45%-60%。主要由 于2024年一季度国内流感爆发以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止的整 个年度因国内没有大规模流行病发生叠加医保控费导致药品终端销量下降；各种形式的带量采购(包括 国家药品集采及地方联盟集采)范围扩大以及国内外行业竞争加剧带来持续的价格压力；及盐酸溴己新 安瓿注射液因不再通过国家药品集采销售而营业额有所减少。 ...

英矽智能(03696)获纳入恒生综合指数成份股 图达通(02665)获纳入恒生综合指数成份股 长风药业(02652)获纳入恒生综合指数成份股 翰森制药(03692)：甲磺酸阿美替尼片单药治疗于欧盟获批上市 【重大事项】 拨康视云-B(02592)：CBT-199新药临床试验申请已生效，临床试验被认定为可安全推进 石药集团(01093)：GLP -1/GIP受体双偏向性激动多肽长效注射液在美国获临床试验批准 石药集团(01093)：罗哌卡因长效注射液(SYH9089注射液)在中国获临床试验批准 复宏汉霖(02696)：HLX15-SC (重组抗CD38全人单克隆抗体注射液-皮下注射)用于多发性骨髓瘤治疗的1 期临床试验申请获美国FDA批准 【财报数据】 首钢资源(00639)发盈警 预计2025年度公司拥有人应占综合溢利约6亿港元至7亿港元 石四药集团(02005)发盈警，预期年度股权持有人应占溢利同比下降约45%至60% 好孩子国际(01086)发盈警 预期2025年纯利同比下降约35%至 45% 速腾聚创(02498)2025财年激光雷达产品销售持续增长 Q4首次单季实现盈利 ...

估计公司股权持有人应占溢利的下降主要由于以下因素导致营业额下降：(i)2024年一季度国内流感爆发 以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止的整个年度因国内没有大规模流行 病发生叠加医保控费导致药品终端销量下降;(ii)各种形式的带量采购(包括国家药品集采及地方联盟集 采)范围扩大以及国内外行业竞争加剧带来持续的价格压力;及(iii)盐酸溴己新安瓿注射液因不再通过国 家药品集采销售而营业额有所减少。 格隆汇2月16日丨石四药集团(02005.HK)公告，基于董事局目前可获得的资讯及对集团截至2025年12月 31日止年度的未经审核管理账目所作出的初步审阅後，董事局初步估计，截至2025年12月31日止年度之 公司股权持有人应占溢利与截至2024年12月31日止年度之公司股权持有人应占溢利10.61亿港元相比， 集团预计将录得介乎45%至60%的下降。 ...

Core Viewpoint - The company, 石四药集团, anticipates a decline of approximately 45% to 60% in profit attributable to equity holders for the year ending December 31, 2025, compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue caused by several factors, including the lack of large-scale epidemics in the domestic market and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the expansion of various forms of bulk purchasing, including national and local drug procurement, along with intensified competition, will continue to exert price pressure [1] - Revenue from the product, 盐酸溴己新安瓿注射液, has decreased as it is no longer sold through national drug procurement [1] Group 2: Financial Health and Strategy - Despite the anticipated decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, anticipates a significant decline in profit attributable to equity holders, projecting a decrease of approximately 45% to 60% compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue driven by several factors, including the absence of large-scale epidemics and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the absence of major epidemics, which previously boosted demand for intravenous infusions and other medications, will negatively impact sales for the year ending December 31, 2025 [1] - Increased price pressure from expanded volume-based procurement initiatives and intensified competition in both domestic and international markets is also contributing to the anticipated revenue decline [1] Group 2: Financial Health and Strategy - Despite the expected decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內 容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 盈利警告 截至二零二五年十二月三十一日止年度之全年業績 本公告乃石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）根據證券及期貨 條例（香港法例第571章）第 XIVA部之內幕消息條文（定義見香港聯合交易所有限公司證券上 市規則（「上市規則」））及上市規則第13.09(2)條而作出。 本公司董事局（「董事局」）謹此知會本公司股東（「股東」）及有意投資者，基於董事局 目前可獲得的資訊及對本集團截至二零二五年十二月三十一日止年度的未經審核管理賬目所 作出的初步審閱後，董事局初步估計，截至二零二五年十二月三十一日止年度之本公司股權 持有人應佔溢利與截至二零二四年十二月三十一日止年度之本公司股權持有人應佔溢利 1,061,150,000港元相比，本集團預計將錄得介乎45%至60%的下降。 估計本公司股權持有人應佔溢利的下降主要由於以下因素導致 ...

盐酸普萘洛尔主要用于(i)作为二级预防，降低心肌梗死死亡率;(ii)高血压;(iii)劳力型心绞痛;及(iv)控制室 上性快速心律失常及室性心律失常。 石四药集团(02005)发布公告，本集团的盐酸普萘洛尔已获中国国家药品监督管理局批准登记成为在上 市制剂使用的原料药。 ...

盐酸普萘洛尔主要用于(i)作为二级预防，降低心肌梗死死亡率;(ii)高血压;(iii)劳力型心绞痛;及(iv)控制室 上性快速心律失常及室性心律失常。 智通财经APP讯，石四药集团(02005)发布公告，本集团的盐酸普萘洛尔已获中国国家药品监督管理局批 准登记成为在上市制剂使用的原料药。 ...